4//SEC Filing
REED ELIZABETH E 4
Accession 0001283303-25-000005
CIK 0001438533other
Filed
Sep 23, 8:00 PM ET
Accepted
Sep 24, 4:05 PM ET
Size
9.1 KB
Accession
0001283303-25-000005
Insider Transaction Report
Form 4
REED ELIZABETH E
Chief Legal Officer and GC
Transactions
- Exercise/Conversion
Common Stock
2025-09-22$19.08/sh+10,000$190,800→ 99,878 total - Exercise/Conversion
Employee stock option (right to buy)
2025-09-22−10,000→ 40,000 totalExercise: $19.08Exp: 2027-01-04→ Common Stock (10,000 underlying) - Sale
Common Stock
2025-09-22$25.00/sh−10,000$250,000→ 89,878 total
Footnotes (3)
- [F1]Includes 396 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 31, 2025.
- [F2]This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 4, 2017 with an expiration date of January 4, 2027.
- [F3]The stock option is fully vested and exercisable.
Documents
Issuer
Travere Therapeutics, Inc.
CIK 0001438533
Entity typeother
Related Parties
1- filerCIK 0001283303
Filing Metadata
- Form type
- 4
- Filed
- Sep 23, 8:00 PM ET
- Accepted
- Sep 24, 4:05 PM ET
- Size
- 9.1 KB